

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SmithKline Beecham (Cork) Ltd.	08/31/2012
RECEIVING PARTY DATA	
Name:	Neurocrine Biosciences, Inc.
Street Address:	12780 El Camino Real
City:	San Diego
State/Country:	CALIFORNIA
Postal Code:	92130
PROPERTY NUMBERS Total: 4	
Property Type	Number
Patent Number:	7427630
Patent Number:	7737154
Patent Number:	8088779
Patent Number:	7879862
CORRESPONDENCE DATA	
Fax Number:	8587773488
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	8586177777
Email:	jdare@neurocrine.com
Correspondent Name:	Joseph-Stephen DaRe
Address Line 1:	12780 El Camino Real
Address Line 2:	Neurocrine Biosciences, Inc.
Address Line 4:	San Diego, CALIFORNIA 92130
NAME OF SUBMITTER:	Joseph-Stephen DaRe
Total Attachments: 2 source=GSK - NBI assignment 8-31-12#page1.tif source=GSK - NBI assignment 8-31-12#page2.tif	

CH \$160.00 7427630

EXHIBIT D

ASSIGNMENT OF PATENT ASSIGNED ASSETS

SmithKline Beecham (Cork) Ltd., with offices at Currabinny, Carrigaline, County Cork, Ireland ("*Assignor*") hereby assigns certain rights to Neurocrine Biosciences, Inc., with offices at 10555 Science Center Drive, San Diego, California, U.S.A. 92121 ("*Assignee*").

WHEREAS, Assignor is the sole owner of the United States and foreign patents set forth on Schedule I hereto (the "*Patents*"); and

WHEREAS, Assignor has agreed with Assignee for the transfer to it of Assignor's whole right, title and interest in and to such Patents and Inventions described and/or claimed therein.

NOW THIS ASSIGNMENT WITNESSETH THAT, for the consideration provided for in, and pursuant to that certain Termination Agreement between Assignor and the Assignee dated August 31, 2012, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor, as beneficial owner, hereby assigns and transfers to Assignee the whole right, title and interest in and to the Patents, and any and all other patents in the United States or other countries which may be granted therefore and thereon, and in and to any and all reissues or extensions of the Patents or of such other patents, and the full exclusive benefits thereof, and all rights, privileges and advantages appertaining thereto, including the right to claim priority therefrom, including any and all rights to damages, profits or recoveries of any nature for past infringement of the Patents, and the payment of any and all maintenance fees, taxes, and the like, to hold the same unto and to the use of Assignee, its successors and assigns absolutely during the residue of the respective terms for which the Patents and such other patents were granted and during any such terms.

Assignor hereby covenants that Assignor has not executed and will not execute any agreements inconsistent with this Assignment.

Promptly upon Assignee's written request, Assignor hereby agrees to execute such additional form(s) of assignment for the Patents as may be required by the appropriate governmental authority of the United States or any foreign country for recordation of the Assignment. Without limitation, Assignor grants to Assignee the power to insert on this Assignment any further identification that may be necessary or desirable in order to record this Assignment.

Executed at _____ this 31st day of August 2012.

By 

Name Donald E. Galt

Title Director

SCHEDULE 1 TO EXHIBIT D

Assignor and Assignee hereby agree that this Schedule 1 will be identical to Exhibit C2 of the Termination Agreement. Assignee will have the right to prepare multiple versions of this Schedule 1 that list one or more of the Patents for a single country set forth on Exhibit C2 of the Termination Agreement for recordation with the appropriate governmental authority of such country.

PATENT ASSIGNED ASSETS

PB60162A

Country	Status	Application Date	Application Number	Grant Date	Patent Number	Expiration Date
United States	Granted	07-apr-04	10/552493	23-sep-08	7427630	07-apr-24

PB60642

Country	Status	Application Date	Application Number	Grant Date	Patent Number	Expiration Date
United States	Granted	20-dic-04	10/596648	15-jul-10	7737154	19-oct-26

PB61626

Country	Status	Application Date	Application Number	Grant Date	Patent Number	Expiration Date
United States	Granted	28-sep-08	12/067939	03-gen-12	8088779	28-sep-26

PJ61089

Country	Status	Application Date	Application Number	Grant Date	Patent Number	Expiration Date
Canada	Filed	19-oct-05	2584567			
Japan	Granted	19-oct-05	2007-537896	13-gen-12	4801744	19-oct-25
Mexico	Granted	19-oct-05	MX/A/2007/004701	22-jul-11	288808	19-oct-25
United States	Granted	19-oct-05	11/578857	01-feb-11	7879862	28-nov-26

PATENT